Foundation Fighting Blindness

Latest Episodes:

Eye on the Cure Podcast | Episode 42: Paul Bresge Mar 10, 2023

Show notes

March 10, 2023. Paul Bresge, chief executive officer at Ray Therapeutics, talks to host Ben Shaberman about his company’s emerging optogenetic therapy for restoring vision to people with advanced forms of retinitis pigmentosa (RP), Stargardt disease, and geographic atrophy (advanced dry age-related macular degeneration). Paul also reflects on his prior role as chief executive officer at jCyte and how the diagnosis of RP for his daughter changed the trajectory of his career.

Eye on the Cure Podcast | Episode 41: Dean Bok, PhD Feb 24, 2023

Show notes

February 24, 2023. Dean Bok, PhD, a distinguished professor and renowned researcher at UCLA, talks with host Ben Shaberman about his pivotal discovery in the late 1960s of the daily renewal process for photoreceptors in the retina and other early, groundbreaking discoveries about retinal diseases that laid a foundation for therapy development for years to come.

Eye on the Cure Podcast | Episode 40: Rebecca Alexander Feb 10, 2023

Show notes

February 10, 2023. Rebecca Alexander — a psychotherapist, keynote speaker, author, fitness instructor, and disability rights advocate — talks candidly with host Ben Shaberman about her journey with Usher syndrome. Reflecting on her own experiences, she discusses how people with vision loss and their loved ones can practice good emotional care and advocate for their needs.

Eye on the Cure Podcast | Episode 39: Paul Bernstein, MD, PhD Jan 20, 2023

Show notes

January 20, 2023. Paul Bernstein, MD, PhD, from the Moran Eye Center, University of Utah, and a member of the Foundation’s Scientific Advisory Board talks to host Ben Shaberman about his clinical practice for retinal disease patients, his early research into vitamin A metabolism in the retina, and nutrition for people with retinal conditions such as retinitis pigmentosa and Stargardt disease.

Eye on the Cure Podcast | Episode 38: Ben Shaberman Jan 06, 2023

Show notes

January 6, 2023. For the first Eye on the Cure episode for 2023, host Ben Shaberman highlights some of the promising clinical advancement made in therapy development over the last year. His recap includes discussions of emerging treatments from: SparingVision, Atsena Therapeutics, Alkeus, Belite, Apellis, Iveric Bio, MeiraGTx, AGTC, 4DMT, and Opus Genetics, which, after the recording of the episode, reported its acquisition of rights to gene therapies for Best disease and RP (RHO).

Eye on the Cure Podcast | Episode 37: Rando Allikmets, PhD Dec 16, 2022

Show notes

December 16, 2022. Rando Allikmets, PhD, from Columbia University, talks to host Ben Shaberman about his remarkable and serendipitous discovery more than two decades ago of ABCA4, the gene associated with Stargardt disease. The breakthrough changed the trajectory of his career, changed the landscape of Stargardt disease research, and led to the development of gene therapies and visual cycle modulators.

SparingVision Receives Authorization to Launch US Clinical Trial for its Cone-Preserving Treatment Dec 02, 2022

Show notes

The emerging therapy is designed to work independent of the mutated gene causing retinitis pigmentosa

News | Opus Genetics to Launch Gene Therapy Clinical Trial for LCA5 Patients Dec 02, 2022

Show notes

The LCA5 gene therapy will be the first emerging Opus treatment to move into a human study

Eye on the Cure Podcast | Episode 36: Sue Bramhall Dec 02, 2022

Show notes

December 2, 2022. Host Ben Shaberman interviews Sue Bramhall who launched Mind's Eye Travel to host journeys around the world for people with vision loss. Affected with RP, Sue channels her passion for travel and planning to organize group adventures that include great eating, tactile experiences, and other non-visual experiences for her guests. Sighted guides also join the excursions to help along the way. Upcoming trips include Europe, Africa, and New Zealand. Learn more at www.MindsEyeTravel.com.

Eye on the Cure Podcast | Episode 35: Kenji Fujita, MD Nov 18, 2022

Show notes

November 18, 2022. Kenji Fujita, MD, chief medical officer at Atsena Therapeutics, talks to host Ben Shaberman about retinal disease gene therapies including positive results from his company's gene therapy clinical trial for people with Leber congenital amaurosis 1 (GUCY2D mutations) as well as Atsena's emerging gene therapies for X-linked retinoschisis and Usher syndrome type 1B.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Foundation Fighting Blindness

Related Podcasts

Links

Stay Connected